BioSpace News Archive

Further milestone paves the way for production of novel gene therapy drug candidate designed to treat drug-resistant focal epilepsy

Marken, the clinical supply chain subsidiary of UPS Healthcare, announced they are adding a GMP-compliant depot in Los Angeles, California and a new GMP-compliant depot in Kiev, Ukraine.

Alan Kadish, M.D., president of New York Medical College and Touro College and University System, announced patent #10,709,883, issued by the United States Patent and Trademark Office for a revolutionary new bandage using Nano technology.

Venus Medtech Inc., the leading transcatheter heart valve medical device player in China, and Pi-Cardia Ltd., a global leader in the development of non-implant catheter-based solutions for treating heart valve calcification, announced a collaboration to bring Pi-Cardia’s Leaflex™ technology to China.

Complete Response Letter Requests Additional Chemistry, Manufacturing, and Controls (CMC) and Human Factors Information

Nemaura Medical, Inc. issued a presentation outlining potential new applications for monitoring disease progression in Covid-19 patients using Continuous Lactate Monitoring.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of an investigator-sponsored trial (IST) being conducted by Imperial College London to evaluate the efficacy of fostamatinib

MyndTec Inc., an award-winning Canadian medical technology company, and University of Health Network (UHN), Canada’s largest medical research hospital, have announced the extension of an exclusive license agreement.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its second quarter 2020 financial results after the market closes on Tuesday August 4, 2020. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT

Vitro Diagnostics, Inc., dba Vitro Biopharma, jointly with GIOSTAR - a San Diego, California-based institution headed by Dr. Anand Srivastava, a pioneer in stem cell science - announced the results of treatment of a critically ill COVID-19 patient with its lead clinical product AlloRx Stem Cells®.